Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
XTSX:IPA
Price:
6.5 CAD
0.78%
Market Closed
Updated:
May 6, 2024
Immunoprecise Antibodies Ltd
Net Income (Common)
|
Immunoprecise Antibodies Ltd
Net Income (Common) Peer Comparison
Comparables:
ABCL
ARCH
RP
IOT
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Net Income (Common)
-CA$7.3m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Net Income (Common)
-$146.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Net Income (Common)
-CA$5.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-39%
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Net Income (Common)
-CA$69.3k
|
CAGR 3-Years
69%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Innovotech Inc
XTSX:IOT
|
Net Income (Common)
-CA$211.1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-9%
|
CAGR 10-Years
14%
|
See Also
What is Immunoprecise Antibodies Ltd's Net Income (Common)?
Net Income (Common)
-7.3m
CAD
-7.3m
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Net Income (Common) amounts to -7.3m CAD.
What is Immunoprecise Antibodies Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-12%
-12%
Over the last year, the Net Income (Common) growth was -48%. The average annual Net Income (Common) growth rates for Immunoprecise Antibodies Ltd have been -12% over the past three years .
You don't have any saved screeners yet
